Product logins

Find logins to all Clarivate products below.


Diabetic Macular Edema – Epidemiology – Middle East and Africa

Clarivate Epidemiology’s coverage of diabetic macular edema (DME) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of DME for each country, as well as annualized case counts projected to the national population.

Clarivate Epidemiology’s DME forecast will answer the following questions:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of DME over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts five DME patient populations, as follows:

  • Total prevalent cases.
  • DME with mild nonproliferative diabetic retinopathy.
  • DME with moderate nonproliferative diabetic retinopathy.
  • DME with severe nonproliferative diabetic retinopathy.
  • DME with proliferative diabetic retinopathy.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
Report
Uveitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Noninfectious Uveitis–Posterior Segment
Most vision loss from uveitis stems from persistent inflammation in the posterior segment of the eye. While noninfectious anterior uveitis is usually managed effectively with topical steroids,…
Report
Thyroid Eye Disease – Unmet Need – Unmet Need – Thyroid Eye Disease US/EU
Thyroid eye disease (TED) is a rare, vision-threatening autoimmune disorder that typically begins with an active inflammatory phase before progressing to a chronic stage. Amgen’s Tepezza is…
Report
Biosimilars – Forecast – Ophthalmology
In 2024, sales of branded biologics in ophthalmology exceeded $6.7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2024-2034 forecast period…
Report
Dry and Wet Age-Related Macular Degeneration – Current Treatment – Treatment Algorithms: Claims Data Analysis – Wet Age-Related Macular Degeneration (US)
The U.S. market for wet age-related macular degeneration (wet AMD) is in transition as newer therapies, including biosimilars, increasingly enter the treatment algorithm. While intravitreal options…